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Clinical Applications of Parathyroid Hormone Assays
John T. Potts, Jr, M D *

fd. Note - This overview was originally presented at the
International Symposium on Clinical Disorders of Bone
and Mineral Metabolism, May 9-13,1983. The following
list indicates the presentations given in this session at the
Symposium and the contents ofthe corresponding
chapter in the Proceedings of the Symposium published by
Excerpta Medica. The numbers in parentheses refer to
pages in this volume. Complete information about the
contents of the Proceedings can be found at the back of
this issue.

Chemical bioassay for parathyroid h o r m o n e : Validation
and clinical applications. D. Goltzman, H. G o m o l i n , M .
Wexler and J.L. Meakins (6)
Clinical utility of ' m i d ' and 'carboxyl' region specific
assays of parathyroid hormone. C G . Arnaud and L.A.
Zitzner (10)
Amino-terminal radioimmunoassays for human parathyroid hormone. G.V. Segre (14)
The contribution of synthetic human parathyroid hormone of its fragments to parathyroid h o r m o n e measurements. F.A. Tschopp, M.A. Dambacher, and J.A.
Fischer (18)
Comparison of amino- and carboxyl-terminal assay methods. E. Slatopolsky (20)

P r o b l e m s seen today in interpretation of the radioimmunoassay for parathyroid hormone were not understood when Berson, Yalow, Aurbach, and I developed
the first radioimmunoassay for the hormone in 1963,
using bovine parathyroid hormone which Aurbach had
purified. In the last two decades, intensive basic research
has been carried out on parathyroid h o r m o n e , including
structural analysis and chemical synthesis of the hormone f r o m human and other mammalian species. It has
become apparent that the biosynthesis and the metabolism o f t h e h o r m o n e a r e m o r e c o m p l e x than was evident
in 1963. Multiple fragments and possibly even precursors
of the hormone are present in blood of humans and
animals. As a result of these discoveries, attempts have
increased to produce immunoassays that measure specific forms o f t h e hormone of greatest clinical significance.

the h uman molecule. In 1983, Segre and his colleagues
introduced a very sensitive amino-terminal immunoassay developed by immunization with the synthetic
human 1-34 fragment.
Many questions about parathyroid hormone remain to
be answered.
• What assays should be used in different diseases
associated with abnormal function o f t h e parathyroid?
• What isthe biological and pathophysiological meani n g o f the heterogeneity of circulating h o r m o n e t h a t
accounts for the multiple circulating fragments?
• How can we use the assays in the most cost-effective
manner when we evaluate patients with hypercalcemia and hypocalcemia?

In 1970, Arnaud and his colleagues first introduced Cterminal assays, based on the bovine sequence, when
the large concentrations of circulating carboxyl fragments were recognized. Since then there has been a
gradual movement toward the use of human hormone.
Mallette, Marx, and their colleagues recently showed
the value of antisera that recognize the middle region of

• What assays will be most useful in the future?
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Parathyroid hormone is composed of 84 amino acids in
human, porcine, bovine and rat species; the structures
are nonidentical but closely homologous. Biological
activity resides in the amino-terminal portion of the
hormone (residue 2-25). Once it was understood that
fragmentation of the h o r m o n e occurs both within the
gland and in the periphery, due to several as yet uncharacterized enzymes at several sites, obvious questions
were raised about what constitutes the active molecular
species. It is clear that if an amino-terminal fragment was
f o r m e d , it could be biologically active.
We do not know whether the fragments entering the
blood from the gland and those produced by peripheral
metabolism are the same, or whether the same enzymes
are responsible in each site. Some groups (our o w n , for
example) have concentrated on peripheral metabolism,
and others have concentrated on fragmentation within
the gland. These studies all have methodological difficulties, including problems with artifacts. There is need to
develop special techniques to examine the products produced by glandular or peripheral metabolism. Although
progress has been slow, the issues raised are intriguing.
The entire molecule of 84 amino acids is still, by conservative estimates, the most likely candidate to interact
with receptors in bone and kidney, the two k n o w n p r i n cipal target organs, it is also possible, however, that a
biologically active amino-terminal fragment either leaves
the site of cleavage and enters the b l o o d , or is produced
by cleavage at target sites to serve as an alternate or even
sole active molecular species, as Slatopolsky's work suggested (pp. 20 ff.). We have to understand the metabolism of the h o r m o n e not only to know what we are
measuring, but also to define (and measure) all molecules that are candidates for significant biological activity.
Fragments produced include a large fragment of 40 to 50
amino acids, extending from region 30 to 40 to the
carboxyl-terminus (usually referred to as C-fragments)
and an amino-terminal fragment. Carboxyl fragments
disappear f r o m blood more slowly than the intact hormone (which is taken up by tissues and cleaved); hence
there is much more carboxyl fragment than intact molecule in b l o o d . Although several groups have detected an
amino-terminal fragment(s) in the blood, there is general agreement that, if present, its concentration is very
low compared to other hormonal forms. The clearance
half-time of such N-fragments must be very rapid. At
steady state, at least three basic molecular species are
present: the intact hormone, carboxyl fragment(s), and
possibly amino-terminal fragment(s).

Fragments arising f r o m the gland may differ from those
that reenter the blood f r o m peripheral sites. Also,
smaller fragments may be formed f r o m the initial cleavage products. No one today knows how many circulating
fragments exist. As knowledge increases, various assays
can be used more effectively to help discriminate
between primary hyperparathyroidism and tumor hypercalcemia and other related clinical issues.
Arnaud and Zitzner (pp. 10 ff.) summarized their experience with assays that measure the biologically inactive
molecules (carboxyl a n d / o r mid-region fragments). Because of the high concentration of these fragments, the
inert fragments have been measurable with many more
antisera. The contributions by Tschopp, et al (pp. 18 ff.)
and by Slatapolsky summarized the issue of the relative
sensitivity and detection limits required for assays that
measure only the amino-terminal region of the molecule. Arnaud and Slatapolsky discussed the utility of
assays that use antisera based on the middle region (M)
or carboxyl region (C) o f t h e molecule. They emphasized
their clinical utility as an "integrative" index of normal or
abnormal glandular activity both in primary hyperparathyroidism and the secondary hyperparathyroidism of
renal failure. The limitation of such M-assays or C-assays
to measure rapid changes in glandular secretory activity
was also discussed.
It is not yet clear that any single assay, however desirable,
can be used effectively in all clinical disease states where
parathyroid status is to be assessed. Segre (pp. 14 ff.)
presented evidence for the possible wide utility of
amino-terminal assays using an antiserum with the very
high affinity constant needed to detect only the intact
molecule (by an exclusive amino-terminal recognition
site that does not detect inert fragments).
In most instances, endocrinologists apply suppression
tests when overactivity is suspected and stimulation tests
when underactivity is suspected. Until recently, such
approaches have not been practical with parathyroid
hormone because of problems with the heterogeneity of
circulating hormone and varying clearance half-times of
the material produced peripherally.
Segre suggested that stimulation and suppression tests
are now practical. His reports of the stimulation and
suppression effect of varying serum calcium concentration in normal subjects and those with primary hyperparathyroidism confirmed in vivo (excised glands) the
findings observed in vitro (primary cell cultures) by
Habener and Brown that a set point defect in primary
hyperparathyroidism exists.
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